How much does the combination of dabrafenib and trametinib cost in China?

The combination therapy of Dabrafenib (Dabrafenib) and Trametinib (Trametinib) has become an important option for the treatment of BRAF V600E mutation-positive melanoma, lung cancer and other tumors. In recent years, this combination has been approved in China and included in medical insurance, greatly easing the financial pressure on patients. The combined use of the two drugs can delay the occurrence of drug resistance to a certain extent and improve the therapeutic effect. Therefore, it is widely recommended by clinicians as a first-line or second-line treatment option.

In the Chinese market, trametinib (trade name: Megenin) has been launched, available in two specifications: 0.5mg and 2mg. The price of 0.5mg30 tablets is about three to four thousand yuan, while the price of 2mg30 tablets is between more than nine thousand to more than ten thousand yuan. In some areas, the price may be lower due to medical insurance reimbursement. For details, please consult the local hospital pharmacy. Dabrafenib (trade name: Tefilla) has also been included in medical insurance, and its latest price ranges from more than 9,000 to more than 10,000 yuan for the packaging specifications of 75mg*120 tablets. Overall, the monthly cost of combination treatment is about 20,000 yuan before medical insurance.

If patients choose to purchase drugs overseas, the prices will be more affordable. Currently, the original Turkish version of trametinib 2mg 30 tablets is priced at about 7,000 to 8,000 yuan, while the Turkish version of dabrafenib 75mg 120 tablets is priced at about 11,000 yuan. In addition, the Lao market has approved generic versions of these two drugs for marketing, and the ingredients of the drugs are consistent with the original drugs. The price of generic trametinib is more than 1,000 yuan, and the price of generic dabrafenib is about 2,000 yuan. The combined monthly treatment cost of the two is significantly reduced, making it suitable for patients with heavy financial burdens.

In general, the combination treatment of dabrafenib combined with trametinib is relatively mature in China, and the price is supported by medical insurance. If patients have limited budget, they can also consider overseas generic drugs with reliable quality, such as the Laos generic version, which not only has a significantly lower price, but also has drug efficacy that can meet treatment needs. No matter which method of purchasing medicines you choose, it is recommended to use medicines under the guidance of a doctor and obtain medicines through formal channels to ensure the safety and effectiveness of treatment.

Reference materials:https://go.drugbank.com/drugs/DB08911